Table 1 Demographic and clinical characteristics of AS patients, FM patients and HCs.

From: Alterations of the resting-state brain network connectivity and gray matter volume in patients with fibromyalgia in comparison to ankylosing spondylitis

 

AS (n = 82)

FM (n = 38)

HC (n = 61)

Age (years)

31.67 ± 10.00

38.97 ± 11.68

31.44 ± 7.35

Male/female

57/25

11/27

37/24

Disease duration (years)

5 [2–12]

1.75 [0.5-5]

/

Current VAS (0–10)

3 [2-5.25]

4.5 [3–6]

/

Global pain (0–10)

4.5 [2.5-6]

6 [4–8]

/

FSS score

3.94 ± 2.49

3.98 ± 1.12

/

WPI

/

9.17 ± 2.12

/

SSS

/

7.31 ± 1.69

/

HADS-anxiety

/

9.14 ± 3.56

/

HADS-depression

/

8.26 ± 3.12

/

BASDAI

3.24 ± 1.84

/

/

CRP

6.3 [1.3-28.15]

0.8 [0.35–1.4]

/

HLA-B27 positivity

74/82 (91.5%)

2/38 (5.3%)

 

Medication

   

 NSAIDs

51/82 (62.2%)

22/38 (57.9%)

/

 bDMARDs

31/82 (37.8%)

/

/

 Corticosteroids

1/82 (1.2%)

/

/

 Duloxetine

/

15/38 (39.5%)

/

 Pregabalin

/

15/38 (39.5%)

/

  1. AS, ankylosing spondylitis; FM, fibromyalgia; HC, healthy control; VAS, visual, analogous scale; FSS, fatigue severity scale; WPI, widespread pain index; SSS, symptom severity scale; HADS, Hospital anxiety and depression scale; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; CRP, C-reactive protein; NSAIDs, nonsteroidal anti-inflammatory drugs; bDMARDS, biological disease-modifying antirheumatic drugs.
  2. Values represent mean ± SD (normal distribution), median [interquartile range] (skewed distribution) or n (% of total).
Back to article page